Medtronic has published data from a clinical study which demonstrates the efficacy of its new treatment for faecal incontinence.
The company's InterStim Therapy was tested among 120 sufferers of the condition who had previously failed to respond to other treatment options, with the Medtronic implant helping to achieve a reduction in incontinence episodes.
This device functions by applying mild electrical stimulation to the sacral nerves controlling the bladder, sphincter and pelvic floor muscles, with the aim of delivering perfect continence.
Medtronic senior vice-president and neuromodulation president Tom Tefft stated that the studies show the product's efficacy in meeting a pressing clinical need.
He said: "InterStim Therapy has a significant impact on quality of life when few other treatment options exist."
Earlier this month, the company was granted a recommendation from the Food and Drug Administration's circulatory system devices panel for a new pacemaker optimised for safe use with MRI scanners.See all the latest jobs in Medical Devices